AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21224829 — intervention group
Group type: COMPARATOR
Intervention: Proportional pricing
Number of subjects: 308
Study 21224829 — intervention group
Group type: EXPERIMENTAL
Intervention: Small meal purchases
Number of subjects: 308
Study 19650798 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium infusion at CSM
Number of subjects: 30
Study 19650798 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium infusion at APM
Number of subjects: 30
Study 19650798 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine-facilitated recovery at CSM
Number of subjects: 30
Study 19650798 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine-facilitated recovery at APM
Number of subjects: 30
Study 17186970 — intervention group
Group type: EXPERIMENTAL
Intervention: CBA-BMS
Number of subjects: 521
Study 17186970 — intervention group
Group type: COMPARATOR
Intervention: BA-BMS
Number of subjects: 521
Study 17186970 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-CBA-BMS
Number of subjects: 521
Study 17186970 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-CBA-BMS
Number of subjects: 521
Study 17186970 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-BA-BMS
Number of subjects: 521
Study 17186970 — intervention group
Group type: EXPERIMENTAL
Intervention: Angio-BA-BMS
Number of subjects: 521
Study 14663908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral chemotherapy with cytostatic drugs and prednisolone during bronchofibroscopy
Number of subjects: 28
Study 14663908 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 28
Study 11827729 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 0
Study 11827729 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 11827729 — intervention group
Group type: COMPARATOR
Intervention: Celiprolol
Number of subjects: 0
Study 8999375 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant propofol infusion of 200 micrograms/kg/min during the pre-bypass period and fentanyl boluses of 1 mg when required (PH Group)
Number of subjects: 30
Study 8999375 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable propofol infusion (from 43.09 to 22.42 micrograms/kg/min) during the pre-bypass period and a fixed infusion of 10.47 micrograms/kg/min during the post-bypass period (PL Group)
Number of subjects: 30
Study 8999375 — intervention group
Group type: COMPARATOR
Intervention: 1% isoflurane administration throughout the intraoperative period (F Group)
Number of subjects: 30
Study 1473327 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetes care system with enhanced role of diabetes specialist nurse
Number of subjects: 700
Study 1473327 — intervention group
Group type: COMPARATOR
Intervention: Standard unaltered clinics
Number of subjects: 700
Study 1473327 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated diabetes care system
Number of subjects: 700
Study 6507711 — intervention group
Group type: EXPERIMENTAL
Intervention: Heel pads, ultrasound, and exercises
Number of subjects: 33
Study 6507711 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound and exercises
Number of subjects: 33
Study 31634245 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel ultrasound group (acoustic shadowing)
Number of subjects: 79
Study 31634245 — intervention group
Group type: COMPARATOR
Intervention: Traditional ultrasound group
Number of subjects: 79
Study 28850378 — intervention group
Group type: EXPERIMENTAL
Intervention: Vapocoolant spray (V)
Number of subjects: 300
Study 28850378 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray (S)
Number of subjects: 300
Study 26323735 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine plus propofol (Ketofol)
Number of subjects: 60
Study 26323735 — intervention group
Group type: COMPARATOR
Intervention: Ketamine alone
Number of subjects: 60
Study 23311540 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 gm MgSO4 as a single bolus (Group A, 16 patients)
Number of subjects: 50
Study 23311540 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 gm MgSO4 (two 4 gm doses q4H) (Group B, 8 patients)
Number of subjects: 50
Study 23311540 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 gm MgSO4 (three 4 gm doses q4H) (Group C, 8 patients)
Number of subjects: 50
Study 23311540 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 gm MgSO4 (four 4 gm doses q4H) (Group D, 8 patients)
Number of subjects: 50
Study 23311540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group, 10 patients)
Number of subjects: 50
Study 23311540 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 gm MgSO4
Number of subjects: 50
Study 23311540 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 50
Study 21711463 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium extract at 2% for 2 months
Number of subjects: 0
Study 21711463 — intervention group
Group type: COMPARATOR
Intervention: Glycolic acid (reference resurfacing molecule)
Number of subjects: 0
Study 21711463 — intervention group
Group type: EXPERIMENTAL
Intervention: Achillea millefolium extract
Number of subjects: 0
Study 19419855 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacarbazine with oblimersen
Number of subjects: 1085
Study 19419855 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 1085
Study 19419855 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine, cisplatin, interferon‐alfa‐2b with/without interleukin‐2
Number of subjects: 1085
Study 16886975 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 4,000 mg over 15 min
Number of subjects: 48
Study 16886975 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV) 2,500 mg over 5 min
Number of subjects: 48
Study 16886975 — intervention group
Group type: COMPARATOR
Intervention: Levetiracetam (LEV) administered IV
Number of subjects: 48
Study 15617949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind group (active drug and placebo)
Number of subjects: 4295
Study 15617949 — intervention group
Group type: COMPARATOR
Intervention: Nonblind group (active drug and no treatment)
Number of subjects: 4295
Study 15617949 — intervention group
Group type: EXPERIMENTAL
Intervention: Blind group
Number of subjects: 4295
Study 15617949 — intervention group
Group type: COMPARATOR
Intervention: Nonblind group
Number of subjects: 4295
Study 11020259 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum, Lactobacillus acidophilus and oligofructose (c.1011 cfu of B. longum BB 536 and L. acidophilus NCFB 1748 and 15 g oligofructose daily)
Number of subjects: 30
Study 11020259 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose only
Number of subjects: 30
Study 11020259 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9345328 — intervention group
Group type: COMPARATOR
Intervention: PBSCT
Number of subjects: 48
Study 9345328 — intervention group
Group type: COMPARATOR
Intervention: alloBMT
Number of subjects: 48
Study 9345328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 8246751 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline slow-release tablet
Number of subjects: 0
Study 8246751 — intervention group
Group type: COMPARATOR
Intervention: Theophylline syrup
Number of subjects: 0
Study 3898281 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymopentin (50 mg administered subcutaneously)
Number of subjects: 96
Study 3898281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 30216777 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental prosocial condition (children told the prize would go to another child)
Number of subjects: 240
Study 30216777 — intervention group
Group type: COMPARATOR
Intervention: Control condition (children told they would keep the prize for themselves)
Number of subjects: 240
Study 31050816 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified triangular flap
Number of subjects: 0
Study 31050816 — intervention group
Group type: COMPARATOR
Intervention: Envelope flap
Number of subjects: 0
Study 27506185 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-obturator tape (TOT)
Number of subjects: 195
Study 27506185 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 195
Study 25113246 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab (IVB)
Number of subjects: 30
Study 25113246 — intervention group
Group type: COMPARATOR
Intervention: Posterior subtenon triamcinolone (PST)
Number of subjects: 30
Study 24083754 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and cyclophosphamide six-cycle therapy (TC6)
Number of subjects: 43
Study 24083754 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel followed by 5FU, epirubicin and cyclophosphamide (T-FEC)
Number of subjects: 43
Study 21459680 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg
Number of subjects: 269
Study 21459680 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 50 mg
Number of subjects: 269
Study 21459680 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 100 mg followed by 50 mg
Number of subjects: 269
Study 21459680 — intervention group
Group type: COMPARATOR
Intervention: Celecoxib 50 mg bid
Number of subjects: 269
Study 18366084 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic skin flattening (PSF)
Number of subjects: 40
Study 18366084 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment using the dynamic cooling device (DCD)
Number of subjects: 40
Study 16547714 — intervention group
Group type: COMPARATOR
Intervention: Innovator cyclosporine
Number of subjects: 28
Study 16547714 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic cyclosporine
Number of subjects: 28
Study 15385220 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom-based harm minimization programme conducted in two phases over 2 years.
Number of subjects: 2300
Study 11204035 — intervention group
Group type: EXPERIMENTAL
Intervention: Common spatial patterns analysis of EEG
Number of subjects: 3
Study 9414975 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedotozine 30 mg three times daily
Number of subjects: 271
Study 9414975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271
Study 8503552 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher doses of allergen-antibody complexes (Group A)
Number of subjects: 39
Study 8503552 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower doses of allergen-antibody complexes (Group B)
Number of subjects: 39
Study 8503552 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group C)
Number of subjects: 39
Study 3493493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferential current stimulation (ICS)
Number of subjects: 40
Study 3493493 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 40
Study 30400116 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tsDCS (2, 2.5, and 3 mA for 20 minutes)
Number of subjects: 9
Study 30400116 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tsDCS (2, 2.5, and 3 mA for 20 minutes)
Number of subjects: 9
Study 28780558 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Play in ASP intervention (7-month duration)
Number of subjects: 0
Study 28780558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 25461493 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockable rhythm 1min post-shock
Number of subjects: 1657
Study 25461493 — intervention group
Group type: EXPERIMENTAL
Intervention: Shockable rhythm immediately before next possible shock
Number of subjects: 1657
Study 25461493 — intervention group
Group type: EXPERIMENTAL
Intervention: Return of spontaneous circulation (ROSC)
Number of subjects: 1657
Study 23116683 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRI plus cetuximab
Number of subjects: 666
Study 23116683 — intervention group
Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 666
Study 21040126 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal advancement flap (MAF)
Number of subjects: 18
Study 21040126 — intervention group
Group type: COMPARATOR
Intervention: Primary closure (PC)
Number of subjects: 18
Study 18209768 — intervention group
Group type: EXPERIMENTAL
Intervention: Low absolute hematocrit values during follow-up
Number of subjects: 0
Study 18209768 — intervention group
Group type: COMPARATOR
Intervention: Decreases in hematocrit during follow-up compared with baseline
Number of subjects: 0
Study 17030680 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFA)
Number of subjects: 104
Study 17030680 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone therapy
Number of subjects: 104
Study 12746781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continue secondary prophylaxis
Number of subjects: 0
Study 12746781 — intervention group
Group type: COMPARATOR
Intervention: Discontinue secondary prophylaxis
Number of subjects: 0
Study 10867681 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of migration and reasons for staying overnight as risk factors for malaria.
Number of subjects: 0
Study 10867681 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of prevention as a risk factor affecting prevalence of malaria.
Number of subjects: 0
Study 7612555 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative application of mitomycin C (0.1 mg/ml for 5 minutes)
Number of subjects: 54
Study 7612555 — intervention group
Group type: COMPARATOR
Intervention: Simple excision without mitomycin C
Number of subjects: 54
Study 1369849 — intervention group
Group type: EXPERIMENTAL
Intervention: Obturator neurectomy
Number of subjects: 34
Study 25237 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg etilefrin
Number of subjects: 60
Study 25237 — intervention group
Group type: COMPARATOR
Intervention: 2 mg dihydroergotamine
Number of subjects: 60
Study 31429006 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine sulfate (1500 mg once/day) in addition to conventional therapy
Number of subjects: 108
Study 31429006 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy alone
Number of subjects: 108
Study 31122188 — intervention group
Group type: EXPERIMENTAL
Intervention: CGRP mAbs (any preventive)
Number of subjects: 29
Study 31122188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29479923 — intervention group
Group type: EXPERIMENTAL
Intervention: Protective pressure ventilation
Number of subjects: 60
Study 29479923 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation
Number of subjects: 60
Study 25284704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg oral dose) with STN‐DBS ON
Number of subjects: 16
Study 25284704 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (150 μg oral dose) with STN‐DBS OFF
Number of subjects: 16
Study 25284704 — intervention group
Group type: COMPARATOR
Intervention: Placebo with STN‐DBS ON
Number of subjects: 16
Study 25284704 — intervention group
Group type: COMPARATOR
Intervention: Placebo with STN‐DBS OFF
Number of subjects: 16
Study 22328460 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral pain management program (6 sessions for children, 1 meeting for parents)
Number of subjects: 29
Study 22328460 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (WLC)
Number of subjects: 29
Study 21204682 — intervention group
Group type: EXPERIMENTAL
Intervention: Biking alone with iPod
Number of subjects: 229
Study 21204682 — intervention group
Group type: EXPERIMENTAL
Intervention: Biking alone with a friend
Number of subjects: 229
Study 21204682 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking alone with iPod
Number of subjects: 229
Study 21204682 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking alone with a friend
Number of subjects: 229
Study 21204682 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (biking or walking alone)
Number of subjects: 229
Study 21204682 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercising outdoors
Number of subjects: 229
Study 18468572 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer procedure (rectus fascia sling)
Number of subjects: 48
Study 18468572 — intervention group
Group type: COMPARATOR
Intervention: Older procedure (mesh sling)
Number of subjects: 48
Study 18468572 — intervention group
Group type: EXPERIMENTAL
Intervention: General perception of newer procedures
Number of subjects: 48
Study 16902083 — intervention group
Group type: EXPERIMENTAL
Intervention: Home chemotherapy
Number of subjects: 38
Study 16902083 — intervention group
Group type: COMPARATOR
Intervention: Hospital clinic-based chemotherapy
Number of subjects: 38
Study 14712894 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium bromide
Number of subjects: 0
Study 14712894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14712894 — intervention group
Group type: COMPARATOR
Intervention: Ipratropium bromide
Number of subjects: 0
Study 11130089 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol, 50 micrograms intravaginally every 6 hours for a maximum of 24 hours
Number of subjects: 210
Study 11130089 — intervention group
Group type: COMPARATOR
Intervention: Dinoproston, 0.5 mg intracervically every 12 hours for a maximum of 24 hours
Number of subjects: 210
Study 11130089 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 210
Study 11130089 — intervention group
Group type: COMPARATOR
Intervention: Dinoproston
Number of subjects: 210
Study 9387966 — intervention group
Group type: EXPERIMENTAL
Intervention: Manoeuvre 1 (fast inspiration without an end‐inspiratory pause)
Number of subjects: 11
Study 9387966 — intervention group
Group type: COMPARATOR
Intervention: Manoeuvre 2 (slow inspiration with an end‐expiratory pause of approximately 5 s)
Number of subjects: 11
Study 9387966 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal expiratory flows at the same lung volume with manoeuvre 1
Number of subjects: 11
Study 9387966 — intervention group
Group type: COMPARATOR
Intervention: Maximal expiratory flows at the same lung volume with manoeuvre 2
Number of subjects: 11
Study 8339645 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium infusion (6 g MgSO4 i.v. over 16 h)
Number of subjects: 20
Study 8339645 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 20
Study 3732368 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily administration of beclomethasone dipropionate aerosol
Number of subjects: 0
Study 3732368 — intervention group
Group type: COMPARATOR
Intervention: Four-times daily administration of beclomethasone dipropionate aerosol
Number of subjects: 0
Study 29985226 — intervention group
Group type: COMPARATOR
Intervention: Plyometric group (PG)
Number of subjects: 23
Study 29985226 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength group (SG)
Number of subjects: 23
Study 27073236 — intervention group
Group type: EXPERIMENTAL
Intervention: Irregular shape of hematoma
Number of subjects: 2066
Study 27073236 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterogeneous density of hematoma
Number of subjects: 2066
Study 24881023 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based follow-up
Number of subjects: 229
Study 24881023 — intervention group
Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 229
Study 22326841 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (DM) 60 mg/day
Number of subjects: 250
Study 22326841 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 20230725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol
Number of subjects: 30
Study 20230725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 g/kg)
Number of subjects: 30
Study 18616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency (RF) energy delivery
Number of subjects: 36
Study 18616516 — intervention group
Group type: COMPARATOR
Intervention: Proton pump inhibitor (PPI) regimen
Number of subjects: 36
Study 18616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life scores
Number of subjects: 36
Study 18616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal acid exposure (OAE)
Number of subjects: 36
Study 18616516 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe complications
Number of subjects: 36
Study 15710761 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release paclitaxel-eluting stents (SR)
Number of subjects: 536
Study 15710761 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-release paclitaxel-eluting stents (MR)
Number of subjects: 536
Study 15710761 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stents (BMS)
Number of subjects: 536
Study 12428223 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (30, 75, or 150 mg) once daily
Number of subjects: 309
Study 10327336 — intervention group
Group type: EXPERIMENTAL
Intervention: EPI T1W sequence
Number of subjects: 70
Study 10327336 — intervention group
Group type: COMPARATOR
Intervention: TSE T1W sequence
Number of subjects: 70
Study 10327336 — intervention group
Group type: COMPARATOR
Intervention: UTSE T2W sequence
Number of subjects: 70
Study 10327336 — intervention group
Group type: COMPARATOR
Intervention: TSE T1W - UTSE T2W
Number of subjects: 70
Study 10327336 — intervention group
Group type: COMPARATOR
Intervention: EPI T1W - UTSE T2W
Number of subjects: 70
Study 8932547 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 0
Study 8932547 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox
Number of subjects: 0
Study 8932547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 8932547 — intervention group
Group type: COMPARATOR
Intervention: Meloxicam 30 mg
Number of subjects: 0
Study 1616391 — intervention group
Group type: EXPERIMENTAL
Intervention: End-to-end anastomosis
Number of subjects: 86
Study 1616391 — intervention group
Group type: COMPARATOR
Intervention: Side-to-end anastomosis
Number of subjects: 86
Study 6730996 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (Tegretol)
Number of subjects: 72
Study 6730996 — intervention group
Group type: COMPARATOR
Intervention: Barbital (Diemal)
Number of subjects: 72
Study 31122962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot or feasibility trials evaluating feasibility
Number of subjects: 0
Study 31122962 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot or feasibility trials
Number of subjects: 0